Navigation Links
ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Date:8/28/2008

LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ --

- Professor Desire Collen Will Remain as Chairman of the Board and Scientific Advisor

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces today that Patrik De Haes, MD, currently Chief Operating Officer, has been appointed to succeed Professor Desire Collen as the Company's new Chief Executive Officer on September 1, 2008. At the next General Shareholders Meeting Dr. De Haes will be proposed to become a member of the Board of Directors of ThromboGenics. In the mean time, he will be invited to the Board meetings.

ThromboGenics will continue to benefit from Professor Collen's significant scientific and drug discovery knowledge. Professor Collen will remain Chairman of ThromboGenics' Board of Directors. This new structure ensures the continuity of ThromboGenics' senior management.

Dr. De Haes, 50, has considerable international experience across the biotechnology and healthcare sectors spanning more than 20 years. For the last 18 months, Dr. De Haes has been ThromboGenics' Chief Operating Officer overseeing the Company's daily operations. During this period, he has been a key member of the management team that has achieved a number of transforming milestones for ThromboGenics. These include initiating the clinical development of the Company's unique anti-cancer agent TB-403, and the subsequent development deal for potentially up to EUR500 million with Roche. Dr. De Haes has also been a major contributor to the development strategy of ThromboGenics' lead product, microplasmin, which the Company plans to advance into Phase III clinical trials in early 2009 for the treatment of a number of important eye diseases.

Prior to joining ThromboGenics, Dr. De Haes was Head of the Global Insulin Infusion Business at Roche Diagnostics in Bern, Switzerland, and a member of the Executive Commit
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
2. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
3. ThromboGenics N.V. - Business Update
4. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
5. ThromboGenics Announces 2007 Full Year Results
6. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
7. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
8. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
9. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
10. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
11. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Md. , July 30, 2014 ... components to interrogate biology, but such devices can ... As such, researchers have looked ... in vitro metabolic engineering to characterize ... a chip. New devices are envisioned to recreate ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... 2014 Vala Sciences was recently ... Protection Agency (EPA). This new contract was awarded ... including tests designed to assess the effect of ... of connections between neurons (synapses), which are critical ... formation by environmental pollutants likely contributes to a ...
(Date:7/30/2014)... July 30, 2014 LayerBio, Inc., an ... of its first round of seed financing from friends ... preliminary efforts to develop a novel sustained-release product for ... our investors and their commitment to this important work," ... "Ophthalmology is one of many areas in which innovations ...
Breaking Biology Technology:UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... NEW YORK, April 4, 2011 Reportlinker.com ... is available in its catalogue: ... companies http://www.reportlinker.com/p0203535/Antiviral-Therapeutics---Technologies-markets-and-companies.html ... current state-of-art of antiviral approaches including vaccines, ...
... NEW YORK, April 4, 2011 Scientists at Polytechnic ... NYU College of Dentistry have discovered a biochemical version ... the "peanut butter and chocolate" rule:  Sometimes two things ... https://photos.prnewswire.com/prnh/20091027/NY99197LOGO ) Seiichi Yamano , ...
... 4, 2011 CryoLife, Inc. (NYSE: CRY ), ... announced today that it has filed an IDE ... begin clinical trials for the purpose of obtaining Pre-Market Approval ... during surgical procedures or following traumatic injuries. ...
Cached Biology Technology:Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies 2Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies 3Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies 4New Research Holds Promise for Gene Engineering and Therapy 2New Research Holds Promise for Gene Engineering and Therapy 3New Research Holds Promise for Gene Engineering and Therapy 4CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4
(Date:7/30/2014)... change on the world,s animal and plant species ... a new paper by a research team from ... other organizations. The authors claim that most of ... it comes to climate change. , While ... the "direct" threats of changing temperatures and precipitation ...
(Date:7/30/2014)... Press (OUP) is pleased to announce its new relationship ... 2015, OUP and CINP will partner to publish ... a fully open-access journal. , Alan Frazer, Editor-in-Chief of ... size and expertise of OUP will further facilitate the ... of the very leading journals within neuropsychopharmacology. The conversion ...
(Date:7/30/2014)... July 30, 2014 ResearchMoz ... Government Biometric Systems Market 2014-2024   Business Strategies, Industry ... Biometric Systems Market 2014-2024" offers the reader detailed ... the next ten years, alongside potential market opportunities ... forecasts. To view the table of ...
Breaking Biology News(10 mins):Conservation scientists asking wrong questions on climate change impacts on wildlife 2OUP to partner with the International College of Neuropsychopharmacology 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... , This release is available in French . ... affects over 12 million people worldwide, with more than 2 million ... how the parasite survives inside human cells. That mystery has now ... Signaling by a team led by Dr. Martin Olivier ...
... of liquorice during pregnancy could adversely affect their child,s ... study of eight year old children whose mothers ate ... not perform as well as other youngsters in cognitive ... poor attention spans and show disruptive behaviour such as ...
... Vaccination can lower children,s risk of allergy. Cathleen ... for allergy prevention in the current issue of ... 625-31). Allergic diseases are becoming increasingly common in ... based treatment of allergic asthma, hay fever, or atopic ...
Cached Biology News:Major discovery opens door to leishmania treatment 2Eating liquorice in pregnancy may affect a child's IQ and behavior 2
... trays are disposable trays that ... that have been blotted onto ... eight 10.5 cm x 5 ... cut from blotted membrane and ...
... The ProteoPrep 20 Plasma Immunodepletion Kit specifically ... from human plasma or serum in preparation ... deeper penetration into the plasma proteome whether ... or multidimensional chromatography or go straight to ...
... introduced the industry's first siRNA sequence design ... to keep these tools consistent with new ... the field of RNAi. With the ... RNAi design tools, OligoEngine is pleased to ...
... Signal Enhancer does for enzyme-/substrate-based blotting what intensifying ... the signal up to 10-fold (or one order ... Western Blot Signal Enhancer membrane treatment is a ... to your current Western blotting protocol. The result ...
Biology Products: